Clinical Trial Update: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cisplatin with or without veliparib in patients with recurrent or metastatic triple-negative or BRCA mutation-associated breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer with Brain Metastases
• Breast Cancer with Brca Mutation
• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-04-08